At 36 months , the mean percent TV reduction from baseline was 44 12.7 % ( SD ) in the placebo group , 41 21.0 % in the 0.01 mg MRrhTSH group , and 53 18.6 % in the 0.03 mg MRrhTSH group , with no statistically significant differences among the groups , p = 0.105 .